Promedior

Promedior has built a strong team experienced in developing, advancing, and commercializing products for a wide range of disorders including orphan diseases. The company has successfully advanced its lead therapeutic candidate into Phase 2 human clinical trials. Promedior is supported by leading global healthcare venture investors and has secured important intellectual property relating to the pioneering discoveries and applications of the company's therapeutics.

Proprietary platform: Promedior's drug candidates are based on Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. Normal wound healing involves the inflammation, proliferation, and resolution pathways. Fibrosis occurs when the normal wound healing response gets locked into the proliferation pathway, resulting in scar tissue and, ultimately, organ dysfunction and potentially death.